不同激素受体状态乳腺癌趋化因子CCL5的表达及临床意义  

Expression of chemokine CCL5 in breast cancer with different hormone receptor status and its clinical significance

作　　者：朱永云 李娟娟[2] 陈创[2] 赵迎春 

机构地区：[1]芜湖市第二人民医院甲状腺乳腺外科,241000 [2]武汉大学人民医院乳腺甲状腺外科,400060

出　　处：《中华乳腺病杂志（电子版）》2016年第2期71-75,共5页Chinese Journal of Breast Disease(Electronic Edition)

基　　金：国家自然科学基金青年基金资助项目(81302314)

摘　　要：目的探讨不同激素受体状态乳腺癌组织中趋化因子CCL5表达的临床意义。方法应用免疫组织化学SP法检测2008年1月至2010年1月芜湖市第二人民医院121例浸润性乳腺癌手术患者组织石蜡样本中CCL5的表达,采用χ^2检验分析CCL5与临床病理因素关系,并运用单因素和多因素生存分析不同激素受体状态乳腺癌组织中CCL5表达的预测价值。结果乳腺癌组织中CCL5表达与淋巴结状态有关（χ^2=18.676,P〈0.001）。CCL5阳性组的5年DFS显著低于CCL5阴性组（χ^2=5.089,P=0.024）,淋巴结状态阳性组的5-DFS显著低于淋巴结状态阴性组（χ^2=26.105,P〈0.001）。进一步多因素分析显示,淋巴结状态是乳腺癌患者5年DFS的独立预后因素（RR=5.453,95%CI：2.589-11.485,P〈0.001）。激素受体阳性患者中,CCL5阳性组的5年DFS显著低于CCL5阴性组（χ^2=10.535,P=0.001）,淋巴结状态阳性组的5年DFS显著低于淋巴结状态阴性组（χ^2=11.439,P=0.001）,不同组织学分级组患者间5年DFS差异具有统计学意义（χ^2=6.024,P=0.049）,进一步多因素分析显示,CCL5是激素受体阳性乳腺癌患者5年DFS的独立预后因素（RR=3.205,95%CI：1.052-9.762,P=0.040）,淋巴结状态是激素受体阳性乳腺癌患者5年DFS的独立预后因素（RR=3.915,95%CI：1.191-12.872,P=0.025）。结论不同激素受体状态乳腺癌组织中CCL5的表达,能为乳腺癌内分泌治疗提供更准确诊疗依据。Objective To investigate the expression of chemokine CCL5 in breast cancer with different hormone receptor status and its clinical significance. Methods The expression of CCL5 in paraffin-embedded samples was analyzed in 121 cases of invasive breast cancer treated in Wuhu Second People＇s Hospital from January 2008 to January 2010 using immunohistochemical SP technique. χ~2test was used to detect the relationship between CCL5 expression and clinicopathologic parameters. The survival analysis was used to detect the prognostic value of CCL5 in breast cancer tissue with different hormone receptor status. Results CCL5 expression in breast cancer tissue was related to lymph node status（χ~2= 18. 676,P〈0. 001）.The 5-year DFS in CCL5 positive group was significantly lower than that in CCL5 negative group（χ~2= 5. 089,P = 0. 024）;the 5-year DFS in positive lymph node group was significantly lower than that in negative lymph node group（χ^2=26. 105,P〈0. 001）. The multivariate analysis showed that lymph node status was an independent prognostic factor for 5-year DFS of breast cancer patients（RR = 5. 453,95% CI：2. 589- 11. 485,P 0. 001）. In the patients with hormone receptor positive,the 5-year DFS in CCL5 positive group was significantly lower than that in CCL5 negative group（χ^2= 10. 535,P = 0. 001）;the 5-year DFS in positive lymph node group was significantly lower than that in negative lymph node group（χ^2= 11. 439,P〈0. 001）;the 5-year DFS showed a significant difference among the patients with breast cancer of different histological grades（χ^2= 6. 024,P =0. 049）.CCL5 and lymph node status were independent prognostic factors for 5-year DFS in patients with hormone receptor positive breast cancer（RR = 3. 205,95%CI：1. 052-9. 762,P = 0. 040;RR = 3. 915,95%CI：1. 191-12. 872,P = 0. 025）. Conclusion CCL5 expression in breast cancer tissue with different hormone receptor status can provide important reference in clinical management of breast cancer.

关 键 词：乳腺肿瘤 趋化因子CCL5 预后 

分 类 号：R737.9[医药卫生—肿瘤]